Management of Brain Metastases

Acute Seizure Control and Anticonvulsant Therapy

The National Comprehensive Cancer Network recommends avoiding enzyme-inducing anticonvulsants, such as phenytoin and carbamazepine, as they can interfere with chemotherapy metabolism in patients with brain metastases 1
The Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) recommend levetiracetam and lamotrigine as preferred anticonvulsants in brain tumor patients due to their efficacy and tolerability 2
Levetiracetam has a good tolerability profile and minimal drug interactions with chemotherapeutic agents, making it a preferred option 2
Lamotrigine is another preferred option but requires several weeks to reach therapeutic levels 2

The National Comprehensive Cancer Network suggests starting dexamethasone at 4-8 mg/day in divided doses for patients with brain metastases, with higher doses considered for more acute neurologic issues 1
The National Comprehensive Cancer Network recommends tapering steroids as quickly as the clinical situation allows to minimize long-term toxicity in patients with brain metastases 1

The National Comprehensive Cancer Network recommends MRI with contrast as the gold standard for assessing the number, size, and location of brain metastases, and determining the presence of oligometastases or diffuse multifocal disease 1
The National Comprehensive Cancer Network suggests using CT scan of chest and abdomen or FDG-PET scan to assess the extent of systemic disease and determine whether systemic disease progression is present or isolated to the CNS 1

The National Comprehensive Cancer Network recommends considering surgical decompression for patients with significant midline brain shift, ventricular compression, or massive brain edema, and surgery may be indicated for single accessible lesions causing significant mass effect 1
The National Comprehensive Cancer Network suggests whole brain radiation therapy (WBRT) for patients with multiple (≥4) lesions 1

Prophylactic anticonvulsants should NOT be administered to patients without a history of seizures, with a strength of evidence supporting this recommendation (Level I, D recommendation) 1, 3, 2
Patients with brain tumors already have an elevated seizure risk, with 35-70% of patients experiencing seizures 3
If the patient has confirmed seizures, secondary prophylaxis would be indicated until local tumor control is achieved 2
Regular neurological assessment for seizure activity is essential, and MRI monitoring is necessary, as worsening of a pre-existing seizure disorder often indicates tumor progression 2

Pain management is essential for quality of life in patients with brain metastases, but medication choices must balance symptom relief against potential adverse effects and drug interactions 3, 2